Passage Bio Inc Dossier - Source-backed chat

Passage Bio Inc

PASGNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.28

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.20Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $13.5M

Enterprise Value −$10.6M

Shares Outstanding 3.2M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Passage Bio is at a critical strategic crossroads. Following the FDA's Type C meeting feedback requiring a randomized controlled trial (RCT) for its lead gene therapy candidate PBFT02 in FTD-GRN, the company has closed the upliFT-D trial to new enrollment, initiated a comprehensive strategic review process, and slashed its workforce by 75% to conserve cash. With only $33.3 million in cash as of March 31, 2026, and an active going-concern warning, the company's survival depends entirely on the outcome of its strategic alternatives review (assisted by Wedbush PacGrow). While early biomarker data for PBFT02 showed promising reductions in brain atrophy and stabilization of plasma NfL, the ethical, logistical, and financial hurdles of an RCT make independent development unviable. A 'Hold' is recommended pending the announcement of a strategic transaction.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$15.50

High · most bullish analyst$23.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.0020%

The strategic review process fails to yield a viable transaction, and the company is unable to raise additional capital under its baby-shelf restricted ATM facility. Facing a severe cash crunch and unable to fund independent clinical trials, the company is forced to liquidate its assets or file for bankruptcy protection, resulting in total loss of capital for equity holders.

Base CaseCentral scenario

$8.0055%

The company successfully partners its pipeline or executes a reverse merger that preserves some equity value for current shareholders while shifting the clinical development burden. Operating expenses are severely reduced due to the 75% workforce cut and lease terminations, extending the cash runway into late 2026 or early 2027 while a transaction is finalized.

Bull CaseUpside scenario

$15.0025%

A successful strategic transaction is reached, such as a merger, reverse merger, or acquisition by a larger biopharmaceutical company that values Passage Bio's AAV-based gene therapy platform and promising early clinical data for PBFT02. The acquirer provides the necessary capital and infrastructure to execute the FDA-mandated randomized controlled trials, unlocking the multi-billion dollar market for genetic dementia.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Promising clinical proof-of-concept data for PBFT02, showing a 64% relative reduction in whole brain atrophy and stabilization of plasma NfL compared to natural history controls.
Aggressive cost-containment measures, including a 75% workforce reduction and termination of expensive office and laboratory leases, to maximize remaining cash runway.
Engagement of Wedbush PacGrow to actively pursue strategic alternatives, including mergers, acquisitions, or asset sales.

Key Investment Risks

Going-concern warning issued by management, with only $33.3 million in cash as of March 31, 2026, which is insufficient to fund operations for the next 12 months.
FDA mandate requiring a randomized controlled trial (RCT) for PBFT02, presenting severe ethical, logistical, and financial hurdles that led to the closure of the upliFT-D trial to new enrollment.
Termination of the Gemma Collaboration Agreement, narrowing the company's pipeline and strategic options.

Thesis Invalidation Triggers

Failure to secure a strategic transaction or partnership by the end of 2026.
Rapid depletion of remaining cash reserves due to higher-than-expected restructuring and lease termination fees.
Complete abandonment of the PBFT02 clinical program.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.